Predicting response to interleukin-2 therapy among patients with renal cell carcinoma.
Leppert
John T
JT
Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1738, USA.
Lam
John S
JS
Belldegrun
Arie S
AS
D014408:Biomarkers, Tumor / Q000378:metabolism; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D009362:Neoplasm Metastasis; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D007376:Interleukin-2